A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00784719 |
Recruitment Status :
Completed
First Posted : November 4, 2008
Results First Posted : April 9, 2013
Last Update Posted : April 9, 2013
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dry Eye Syndromes | Drug: CP-690,550 Drug: Cyclosporine Drug: CP-690,550 Vehicle | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 327 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase I/II Prospective, Randomized, Double Masked, Vehicle And Comparator Controlled, Dose Ranging Study Of CP-690,550 In Subjects With Dry Eye Disease. |
Study Start Date : | November 2008 |
Actual Primary Completion Date : | October 2009 |
Actual Study Completion Date : | October 2009 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment 1 |
Drug: CP-690,550
Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks |
Experimental: Treatment 2 |
Drug: CP-690,550
Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks |
Experimental: Treatment 3 |
Drug: CP-690,550
Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks |
Experimental: Treatment 4 |
Drug: CP-690,550
Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks |
Active Comparator: Active comparator |
Drug: Cyclosporine
Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks |
Placebo Comparator: Placebo |
Drug: CP-690,550 Vehicle
Ophthalmic topical solution, dosed at least once/day, 8 weeks |
- Percentage of Participants With Systemic Adverse Events (AEs) [ Time Frame: Baseline up to Week 8 ]An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs are the events which are not localized but occur throughout the systemic circulation.
- Percentage of Participants With Ocular Adverse Events (AEs) [ Time Frame: Baseline up to Week 8 ]An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Ocular AEs are the events which are localized in the ocular region.
- Percentage of Participants With Ocular Tolerability Assessment [ Time Frame: Baseline up to Week 8 ]Ocular tolerability assessment included evaluation of severity and duration of the 5 symptoms: burning/stinging, blurred vision, ocular discomfort, pain, tearing. Severity was assessed on a 4-point scale, where 0=none, 1=mild, 2=moderate and 3=severe. Duration was assessed as immediate (if subsided within 5 minutes [<5 min] after application) or persistent (if continued beyond 5 minutes [>=5 min] after application).
- Percentage of Participants Who Achieved Greater Than or Equal to (>=) 10 Millimeter (mm) Schirmer Wetting Score Without Anesthesia at Week 8 [ Time Frame: Week 8 ]Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 millimeter (mm). If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Time to Achieve >= 10mm Schirmer Test Score Without Anesthesia [ Time Frame: Baseline through Week 8 ]Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Time to Achieve 100 Percent (%) Clearance of Corneal Staining [ Time Frame: Baseline through Week 8 ]Corneal staining was assessed by instilling sodium fluorescein dye in the eye and after 1 to 2 minutes, observing for corneal staining with the aid of a yellow filter and slit lamp. The cornea was divided into five different zones and each corneal zone was graded independently using a 0 to 3 grading scale; where 0=none, 1=slight, 2=moderate, 3=severe. Results from study eye were to be reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Time to Achieve >= 5 Units Decrease in Ocular Comfort Index (OCI) Score [ Time Frame: Baseline through Week 8 ]OCI: validated questionnaire to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contained 12 questions, each measured on a 7-point Likert scale ranging from 0 (never) to 6 (always/severe). Total score was transformed to range of 0 to 100, higher score indicated more ocular discomfort. Negative change from baseline indicated improvement.
- Change From Baseline in Schirmer Wetting Score Without Anesthesia at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Change From Baseline in Schirmer Wetting Score With Anesthesia at Week 8 [ Time Frame: Baseline, Week 8 ]Schirmer test was performed 2 to 3 minutes after 1 drop of proparacaine 0.5% was placed in lower conjunctival fornix and superior bulbar conjunctiva of each eye. It was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Percentage of Participants Who Achieved >=10 mm Schirmer Wetting Score Without Anesthesia at Week 1, 2, 4 and 6 [ Time Frame: Week 1, 2, 4, 6 ]Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Percentage of Participants Who Achieved >=10 mm Schirmer Wetting Score With Anesthesia at Week 8 [ Time Frame: Week 8 ]Schirmer test was performed 2 to 3 minutes after 1 drop of proparacaine 0.5% was placed in lower conjunctival fornix and superior bulbar conjunctiva of each eye. It was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Change From Baseline in Corneal Staining Scores at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]Corneal staining was assessed using fluorescein dye, a yellow filter, and a slit lamp. The cornea was divided into 5 different zones. Each corneal zone was graded independently using a 0 to 3 grading scale; where 0=none, 1=slight, 2=moderate, 3=severe. Sum of scores of each zone led to total score. Total score range: 0 to 15, higher score indicated greater staining. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Percentage of Participants Who Demonstrated 100% Clearance of Corneal Staining [ Time Frame: Week 1, 2, 4, 6, 8 ]Corneal staining was assessed using fluorescein dye, yellow filter, slit lamp. Cornea was divided into 5 different zones. Each corneal zone was graded independently using 0 to 3 grading scale:0=none, 1=slight, 2=moderate, 3=severe. Sum of scores of each zone led to total score. Total score range: 0 to 15, higher score indicated greater staining. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Change From Baseline in Interpalpebral Conjunctival Staining Score at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]Interpalpebral conjunctival staining was performed 1 minute following ocular administration of lissamine green dye with aid of slit lamp. Based on Oxford grading system, bulbar conjunctiva was divided into 2 zones: nasal, temporal. Staining were graded using a 6-point scale (0=absent, 5=severe). Total score=sum of 2 zone scores. Total score range: 0 to 10, higher score=higher damage to eyes due to dryness. Negative change from baseline indicated improvement. Results from study eye are reported. Study eye is the eye with worse Schirmer test score without anesthesia score at baseline.
- Change From Baseline in Tear Break-up Time (TBUT) at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]TBUT was the time interval between the last complete blink and the first appearance of a dry spot, or disruption in the tear film. It was measured under a slit lamp following instillation of fluorescein dye in the eye using a stopwatch. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline.
- Change From Baseline in Ocular Comfort Index (OCI) Score at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]OCI: validated questionnaire to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contains 12 questions, each measured on a 7-point Likert scale ranging from 0 (never) to 6 (always/severe). Total score was transformed to range of 0 to 100, higher score indicated more ocular discomfort. Negative change from baseline indicated improvement.
- Percentage of Participants With >= 5 Units Decrease in Total OCI Score [ Time Frame: Week 1, 2, 4, 6, 8 ]OCI: validated questionnaire to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contains 12 questions, each measured on a 7-point Likert scale ranging from 0 (never) to 6 (always/severe). Total score was transformed to range of 0 to 100, higher score indicated more ocular discomfort.
- Change From Baseline in Daily Artificial Tear Use at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]Daily artificial tear use was assessed by collecting data on daily number of drops of artificial tear instilled in the eye using a participant diary. Decrease in daily artificial tear use indicated improvement.
- Change From Baseline in Ocular Surface Disease Index (OSDI) Total and Subscale Score at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]OSDI is a validated instrument for ocular surface disease. It has 12 items, each measured on 5-point Likert scale (0=none of the time, 4=all the time). Based on these item scores, a total OSDI score (question 1 [Q1]-Q12) and three subscale scores can be derived: Ocular Symptom (Q1-Q3), Vision-related function (Q4-Q9), and Environmental trigger (Q10-Q12). Each derived score ranges from 0 to 100, with a higher score indicates worse condition.
- Percentage of Participants With >= 10 Units Decrease in Total OSDI Score [ Time Frame: Week 1, 2, 4, 6, 8 ]OSDI is a validated instrument for ocular surface disease. It has 12 items, each has a raw score measured on 5-point Likert scale (0=none of the time, 4=all the time). Based on these item scores, a total OSDI score can be derived which ranges from 0 to 100; a higher score indicates worse ocular disease.
- Change From Baseline Ocular Surface Disease Index (OSDI) Raw Score at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]OSDI is a validated instrument for ocular surface disease. It has 12 items, each with a raw score measured on 5-point Likert scale (0=none of the time, 4=all the time).
- Change From Baseline in Modified Ocular Comfort Index (mOCI) Raw Scores at Week 1, 2, 4, 6 and 8 [ Time Frame: Baseline, Week 1, 2, 4, 6, 8 ]mOCI consisted of the original 12-item OCI plus additional questions on other dry eye symptoms and their impact to participant's life. Each item was measured on a 7-point Likert scale ranging from 0 (never) to 6 (always/severe). Negative change from baseline indicated improvement.
- Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item Score (NEI-VFQ-25) at Week 8 [ Time Frame: Baseline, Week 8 ]NEI-VFQ-25 questionnaire included 25 items based on which overall composite VFQ score and 12 subscales were derived: general health (GH), general vision (GV), ocular pain (OP), near activities (NAct), distance activities (DA), social functioning (SF), mental health (MH), role difficulties (RD), dependency, driving, color vision (CV) and peripheral vision (PV). Response to each question converted to 0-100 score. Each subscale, total score=average of items contributing to score. For each subscale and total score, score range: 0 to 100, higher score=less symptoms/better visual functioning.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Symptoms of dry eye for at least 6 months.
- Signs of moderate to severe dry eye
Exclusion Criteria:
- Women who are nursing or pregnant
- Participation in other studies within 30 days of screening visit
- Ocular disorders that may confound interpretation of study results

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00784719
United States, Arizona | |
Pfizer Investigational Site | |
Chandler, Arizona, United States, 85286 | |
Pfizer Investigational Site | |
Peoria, Arizona, United States, 85381 | |
Pfizer Investigational Site | |
Phoenix, Arizona, United States, 85032 | |
United States, California | |
Pfizer Investigational Site | |
Artesia, California, United States, 90701 | |
United States, Colorado | |
Pfizer Investigational Site | |
Centennial, Colorado, United States, 80112 | |
United States, Florida | |
Pfizer Investigational Site | |
Ormond Beach, Florida, United States, 32174 | |
Pfizer Investigational Site | |
Stuart, Florida, United States, 34994 | |
Pfizer Investigational Site | |
Tamarac, Florida, United States, 33321 | |
Pfizer Investigational Site | |
Tampa, Florida, United States, 33603 | |
United States, Georgia | |
Pfizer Investigational Site | |
Atlanta, Georgia, United States, 30342 | |
Pfizer Investigational Site | |
Morrow, Georgia, United States, 30260 | |
Pfizer Investigational Site | |
Roswell, Georgia, United States, 30076 | |
United States, Kentucky | |
Pfizer Investigational Site | |
Louisville, Kentucky, United States, 40217 | |
United States, Maryland | |
Pfizer Investigational Site | |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Pfizer Investigational Site | |
Boston, Massachusetts, United States, 02114 | |
United States, Missouri | |
Pfizer Investigational Site | |
Kansas City, Missouri, United States, 64111 | |
United States, New York | |
Pfizer Investigational Site | |
Lynbrook, New York, United States, 11563 | |
Pfizer Investigational Site | |
Rochester, New York, United States, 14618 | |
United States, North Carolina | |
Pfizer Investigational Site | |
Charlotte, North Carolina, United States, 28210 | |
Pfizer Investigational Site | |
High Point, North Carolina, United States, 27262 | |
United States, Ohio | |
Pfizer Investigational Site | |
Cleveland, Ohio, United States, 44115 | |
Pfizer Investigational Site | |
Columbus, Ohio, United States, 43210 | |
United States, Tennessee | |
Pfizer Investigational Site | |
Memphis, Tennessee, United States, 38119 | |
United States, Texas | |
Pfizer Investigational Site | |
Austin, Texas, United States, 78705 | |
Pfizer Investigational Site | |
Austin, Texas, United States, 78731 | |
Pfizer Investigational Site | |
Austin, Texas, United States, 78746 | |
Pfizer Investigational Site | |
San Antonio, Texas, United States, 78240 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00784719 |
Other Study ID Numbers: |
A3921034 A3921034 |
First Posted: | November 4, 2008 Key Record Dates |
Results First Posted: | April 9, 2013 |
Last Update Posted: | April 9, 2013 |
Last Verified: | February 2013 |
Dry eye |
Keratoconjunctivitis Sicca Dry Eye Syndromes Keratoconjunctivitis Conjunctivitis Conjunctival Diseases Eye Diseases Keratitis Corneal Diseases Lacrimal Apparatus Diseases Cyclosporine Cyclosporins Tofacitinib |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors Protein Kinase Inhibitors |